- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03628937
The Effect of Decaffeinated Green Tea Polyphenol Intake on the Risk of Precocious Puberty Among Obese Girls
April 20, 2020 updated by: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
In this study, 6-10 years old obese girls will be recruited to test the preventive effect of decaffeinated green tea polyphenols on the risk of precocious puberty by the random, placebo-control and single blind design.
The intervention group will be given decaffeinated green tea polyphenols capsule (400mg/d) and the control group will be given placebo.
The oral treatment will be lasted for 12 weeks.Then all the subjects will be followed up every 3 months until three months after menstruation.
At the baseline and after the 12 week intervention, the clinical manifestations of secondary sexual characters, the serum levels of sex hormones will be determined as the outcome variables.
After controlling confounding factors, the preventive effect of the green tea polyphenols on precocious puberty or early puberty among obese girls will be analyzed.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Simple obese girls are prone to premature or early puberty.
The topic proposed based on previous studies, recruiting of 80 simple overweight or obesity girls, aged 6 to 10 years old.
After the informed consent, they will be randomly divided into intervention group and control group, intervention group will be given tea polyphenol capsule (400 mg, epigallocatechin gallate (EGCG) accounted for 50%), the control group given placebo capsule.
Participants need take it once a day after breakfast.
All of them will receive similar health advice on proper diet and exercise.
The intervention will last 12 weeks, followed by telephone every 3 months until 3 months after menarche.
The researchers will measure children obesity index (using artificial detection), youth development index (secondary sex characteristic clinical manifestations, serum sex hormone, B ultrasonic examination uterus ovarian and breast volume, etc.) in three stages: at the baseline, after 12 weeks intervention and the end of three months after menstruation.
The liver and kidney function, blood and urine routine and serum trace elements will be detected before and after the three-month intervention.
Through the above detection of the indicators related to obesity and sexual precocious puberty, it is explored whether the decaffeinated tea polyphenol has preventive effects on precocious puberty.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Department of Clinical Nutrition, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 10 years (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 6-10 years old;
- BMI reached or exceeded the overweight or obesity threshold of school-aged girls in China (6 years old, BMI>=16.3; 7 years old, BMI>=17.2; 8 years old, BMI>=18.1;9 years old, BMI>=19.0; Age of 10, BMI>=20.0);
- having not received sex hormone drugs, gonadotropin-releasing hormone (GnRH) drugs and Chinese medicine for the prevention and treatment of precocious puberty in the past;
- the guardian's informed consent;
Exclusion Criteria:
- secondary obesity (such as hormone therapy);
- weight loss treatment is currently under way;
- menarche or central precocious puberty has been clearly diagnosed;
- patients with serious heart, liver, kidney, hematopoietic system diseases and endocrine genetic metabolic diseases;
- iron therapy is under way;
- patients with acute and chronic inflammation;
- other conditions that the researchers believe may influence the observation results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention group
Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks. Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks |
Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%).
Participants need take it once a day after breakfast for 12 weeks.
|
PLACEBO_COMPARATOR: Control group
The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
|
The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule.
The use frequency and duration are consistent with intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of Precoicous Puberty in the intervention groups and the placebo group.
Time Frame: about two years
|
Female precocious puberty is defined as the development of secondary sexual characteristics before the age of 8 or menarche before the age of 10.
In our study, after intervention, for girls under 8 years of age, we recorded their rate of secondary sexual characteristics at 8 years of age; and for girls under 10 years of age, we recorded their rate of menarche at 10 years of age.
The difference in the incidence of precocious puberty between the two groups is the primary outcome.
|
about two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The average age of onset of menarche in two groups
Time Frame: an average of 4 years
|
Record the age of the onset of menarche of each girl and comparing the average age between two groups, to explore whether green tea polyphenols could delay the early pubertal development.
|
an average of 4 years
|
The change in BMI at week 12 intervention from the baseline
Time Frame: 12 weeks
|
Obesity is an important contributing factor to the early onset of puberty for girls.
Green tea polyphenols may prevent precocious puberty by controlling body weight and reducing serum leptin level.
|
12 weeks
|
The change of breast tissue volume at week 12 intervention from the baseline
Time Frame: 12 weeks
|
These indicator is important indicators related to sexual development.
|
12 weeks
|
The change of uterus volume at week 12 intervention from the baseline
Time Frame: 12 weeks
|
These indicator is important indicators related to sexual development.
|
12 weeks
|
The change of the number of follicles with diameter of > 4mm follicles in ovary at week 12 intervention from the baseline
Time Frame: 12 weeks
|
These indicator is important indicators related to sexual development.
|
12 weeks
|
The change of serum sex hormone levels at week 12 intervention from the baseline
Time Frame: 12 weeks
|
These indicators are important indicators related to sexual development.
|
12 weeks
|
The status of liver and kidney function at the baseline and after 12 weeks intervention
Time Frame: 12 weeks
|
To identify the safety of green tea polyphenol intake for obese girls
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Xiuhua Shen, Professor, Xinhua Hospital Afflicated to Shanghai Jiaotong University of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 28, 2018
Primary Completion (ACTUAL)
January 31, 2020
Study Completion (ANTICIPATED)
July 31, 2023
Study Registration Dates
First Submitted
July 10, 2018
First Submitted That Met QC Criteria
August 9, 2018
First Posted (ACTUAL)
August 14, 2018
Study Record Updates
Last Update Posted (ACTUAL)
April 22, 2020
Last Update Submitted That Met QC Criteria
April 20, 2020
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XH-18-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Obesity
-
Virginia Commonwealth UniversityActive, not recruitingObesity, PediatricUnited States
-
University of British ColumbiaThe Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
-
Hasselt UniversityJessa HospitalCompletedObesity, Pediatric
-
Azienda Ospedaliera Universitaria Integrata VeronaNot yet recruitingObesity, Pediatric
-
University of British ColumbiaHeart and Stroke Foundation of Canada; Public Health Agency of Canada (PHAC); Childhood Obesity Foundation and other collaboratorsCompleted
-
Columbia UniversityCompletedVitamin D Deficiency | Obesity, Morbid | Obesity, Childhood | Obesity, PediatricUnited States
-
University Hospital, Clermont-FerrandAME2P Laboratory, Clermont Auvergne UniversityCompleted
-
Medical College of WisconsinWisconsin Department of Health and Family Services; Children's Health System...TerminatedPediatric Obesity | Pediatric OverweightUnited States
-
Kahramanmaras Sutcu Imam UniversityCompletedPediatric Obesity | Pediatric DentistryTurkey
-
Central Hospital, Nancy, FranceNot yet recruiting
Clinical Trials on Decaffeinated Green Tea Polyphenol
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Anglia Ruskin UniversityCompletedOverweight and Obesity | Fat BurnUnited Kingdom
-
Ain Shams UniversityRecruiting
-
The University of Hong KongCompleted
-
Taipei City HospitalNational Yang Ming UniversityCompletedType 2 Diabetes | HyperlipidemiaTaiwan
-
Chiang Mai UniversityCompletedHyperuricemia | GoutThailand
-
University of ArizonaUnited States Department of DefenseCompletedLung Cancer Prevention
-
University of MinnesotaNational Cancer Institute (NCI)Completed
-
University of Campinas, BrazilFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedDiabetes Mellitus | Diabetic Nephropathy | Arterial HypertensionBrazil
-
Charite University, Berlin, GermanyCompleted